Lupin inches up as its arm gets nod to market generic version of Spiriva
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin inches up as its arm gets nod to market generic version of Spiriva
May-29-2023 09:27 Hrs IST
Lupin is currently trading at Rs. 782.95, up by 3.30 points or 0.42% from its previous closing of Rs. 779.65 on the BSE.
The scrip opened at Rs. 780.15 and has touched a high and low of Rs. 788.20 and Rs. 780.00 respectively.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 799.65 on 15-May-2023 and a 52 week low of Rs. 592.55 on 17-Jun-2022.
Last one week high and low of the scrip stood at Rs. 788.20 and Rs. 766.05 respectively. The current market cap of the company is Rs. 35478.95 crore.
The promoters holding in the company stood at 47.08%, while Institutions and Non-Institutions held 42.52% and 10.40% respectively.
Lupin’s Canada subsidiary -- Lupin Pharma Canada, has received approval from Health Canada to market a generic version of Spiriva (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD), in Canada.
Tiotropium Bromide Inhalation Powder is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also used to relieve wheezing, shortness of breath, coughing, and chest tightness in patients with COPD. Tiotropium Bromide Inhalation Powder (RLD Spiriva) had estimated annual sales of $42 million in Canada.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
